title: First PDE4 inhibitor for psoriasis hits the market but impact is uncertain.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D008389:Marketing of Health Services / Q000639:trends*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010726:Phosphodiesterase Inhibitors; D013792:Thalidomide; C505730:apremilast